Category: Smith & Nephew
Here's a look at some of the top legal news stories for medical device companies this week: Sales reps level $50m sex discrimination suit against Boston Scientific; Zimmer chooses new bellwethers in NexGen knee implant MDL; Boston Scientific executive's killer gets 17 years; Federal appeals court upholds Smith & Nephew's $85m win over Arthrex; Feds extend Biomet's deferred prosecution deal for another year
A federal appeals court upholds an $85 million patent infringement win for Smith & Nephew over Arthrex.
A pair of high-volume orthopedic surgeons say they're skeptical of so-called 'repless' sales models such as Smith & Nephew's Syncera offering.
A pair of high-volume orthopedists who specialize in hip and knee replacement surgeries are skeptical of generic or "repless" sales models, in which medical device companies offer lower-cost implants without a sales rep on hand to advise during the procedure.
Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Smith & Nephew buys outs Colombian distributor; Matchmaking for medtech, Greenberg Traurig looks to bring companies together; Zimmer releases post-Biomet merger numbers
The lobbying spend in Washington hit a 16-year high of nearly $33 million in 2014, as the industry continued its fight to repeal Obamacare's medical device tax.
The medical device industry's lobbying spend hit its highest point since 1998 last year, nearing $33 million, as the industry stepped up its campaign to repeal the medical device tax enacted as part of Obamacare.
Smith & Nephew buys out EuroCiencia Colombia, its distributor in the South American country, for an undisclosed amount.
Smith & Nephew (NYSE:SNN) said yesterday that it acquired its exclusive distributor for Colombia, EuroCiencia Colombia, for an undisclosed amount.
Royal Oak Medical Devices touts its 'repless' generic sales model, saying it can save its hospital customers more than $100,000 a year on their orthopedic implant spends.
Royal Oak Medical Devices says it can save its hospital customers more than $100,000 a year on their orthopedic implant spends, using its so-called 'repless' generic sales model.